As the second-line systemic therapy for NSCLC, nivolumab showed significant improvement in OS versus docetaxel in patients with advanced NSCLC, in both non-squamous and squamous histology, regardless of PD-L1 expression [8, 9]. The gene discussed is CD274; the disease is non-small cell lung carcinoma.